Abstract 58P
Background
Vepdegestrant (ARV-471) is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. Based on results of the phase 2 cohort expansion (VERITAC) of a phase 1/2 study (NCT04072952), vepdegestrant 200 mg once daily (QD) was selected as the recommended phase 3 dose (RP3D). This phase 1 study (NCT05463952) investigated the safety, PK, and preliminary efficacy of vepdegestrant in Japanese patients with ER+/HER2- advanced breast cancer at the RP3D.
Methods
Patients with ER+/HER2- advanced breast cancer who were resistant to standard therapy or for whom no standard therapy was available or who had received ≥2 prior endocrine therapies in any setting were eligible. Vepdegestrant 200 mg was given QD with food. The primary endpoint was dose-limiting toxicities (DLTs) in cycle 1; secondary endpoints included safety, PK, and antitumor activity.
Results
Six female patients were treated; median age was 58 years (range: 47–62). Five patients received ≥3 prior regimens for advanced disease; 5 patients received prior CDK4/6 inhibitors. At the data cutoff (May 4, 2023), median treatment duration was 9.8 weeks (range: 6–28); 2 patients remained on treatment. No DLTs were observed. Four (66.7%) patients experienced adverse events (AEs); none led to dose reduction or discontinuation. Treatment-related AEs were abdominal discomfort, anemia, dizziness, increased alanine aminotransferase, increased aspartate aminotransferase, nausea, and pruritus (1 event each); all were grade 1 except anemia (grade 2). Geometric mean Cmax and AUC24 of vepdegestrant were 630.9 ng/mL and 10,400 ng•hr/mL after a single dose and 1056 ng/mL and 18,310 ng•hr/mL after multiple doses. Two patients demonstrated stable disease at week 24 assessment.
Conclusions
The RP3D of vepdegestrant 200 mg QD was well tolerated in Japanese patients with ER+/HER2- advanced breast cancer. Vepdegestrant will be evaluated in 2 global, randomized phase 3 studies in patients with ER+/HER2- advanced breast cancer: as second/third-line monotherapy in VERITAC-2 (NCT05654623) and as first-line therapy in combination with palbociclib in VERITAC-3 (NCT05909397).
Clinical trial identification
NCT05463952.
Editorial acknowledgement
Editorial support provided by Nathan Yardley, PhD, and Melissa Austin of Apollo Medical Communications, part of Helios Global Group, and funded by Arvinas Operations, Inc.
Legal entity responsible for the study
Pfizer, Inc.
Funding
Pfizer, Inc.
Disclosure
H. Iwata: Financial Interests, Personal, Advisory Board: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Sanofi; Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Pfizer, Sanofi, Taiho; Financial Interests, Personal and Institutional, Steering Committee Member: Chugai, Daiichi Sankyo, AstraZeneca, MSD, Amgen, Sanofi, Novartis, Pfizer, Kyowa Hakko Kirin; Financial Interests, Personal and Institutional, Local PI: Lilly, Bayer, Behringer, Nihon Kayaku. Y. Naito: Financial Interests, Personal, Invited Speaker, Speakers Bureau: Chugai, Pfizer, Eli Lilly, Eisai, AstraZeneca, PDR pharma, Novartis, Gardant, Ono, Takeda, Taiho, Bayer, Nihon Kayaku, Daiichi Sankyo, Bristol, MSD; Financial Interests, Personal, Funding: Roche; Financial Interests, Personal, Local PI: AbbVie, Boehringer Ingelheim, Ono, Chugai, Taiho, Pfizer, AstraZeneca, Gilead, Takeda; Financial Interests, Personal, Steering Committee Member: Daiichi Sankyo; Non-Financial Interests, Personal, Principal Investigator, JCOG: Natera. M. Hattori: Financial Interests, Personal, Speaker’s Bureau: Pfizer. K. Yonemori: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, Sanofi, Genmab, Gliad, OncoXerna, Takeda, Novartis, MSD; Financial Interests, Personal, Invited Speaker: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Ono, BMS, Boeringer Ingerheim, Daiichi Sankyo, Bayer, Jansen, Sanofi; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seagen, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirrin, Nihon Kayaku, Haihe. M. Aizawa, J. Yoshimitsu: Financial Interests, Personal, Full or part-time Employment: Pfizer R&D Japan. Y. Mori, Y. Umeyama: Financial Interests, Personal, Full or part-time Employment: Pfizer R&D Japan; Financial Interests, Personal, Stocks/Shares: Pfizer Inc. T. Mukohara: Financial Interests, Personal, Research Grant: Daiichi Sankyo, Sysmex, Eisai, MSD, Pfizer, Novartis, Sanofi, Chugai, AstraZeneca, Ono; Financial Interests, Personal, Speaker, Consultant, Advisor, Lecture fees: Eisai, Pfizer, Novartis, Chugai, Eli Lilly, AstraZeneca, Kyowa-Kirin, Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract